From now until 13 Dec 2017, get up to 50% OFF for Miltenyi Biotec products. From tissue dissociation, magnetic cell separation, flow cytometry to cell culture, enjoy the best price for quality MACS reagents.
Author: atcghk
Flash Sale | BioVision Assay Kits | Summer Promotion
Period: now until Aug 31st, 2017
Product: selected BioVision assay kits listed below
Discount: 50% off
Code: BVATCG1707
Region: Hong Kong & Macau
Name | Cat# | Size |
Lysozyme Activity Assay Kit (Fluorometric) | K236 | 100 assays |
Lysozyme Inhibitor Screening Kit | K237 | 100 assays |
PicoProbe™ D-2-Hydroxyglutarate Dehydrogenase Assay Kit (Fluorometric) | K248 | 100 assasys |
Antibody/Protein Aggregation Assay Kit | K308 | 100 assays |
Angiotensin II Converting Enzyme (ACE2) Inhibitor Screening Kit | K310 | 100 assays |
Crystal Violet Cell Cytotoxicity Assay Kit | K329 | 1000 assays |
Neutral Red Cell Cytotoxicity Assay Kit | K447 | 1000 assays |
HDAC6 Inhibitor Screening Kit (Fluorometric) | K465 | 100 assays |
HDAC6 Activity Assay Kit (Fluorometric) | K466 | 100 assays |
Org Frontier™ Chloroplast Isolation Kit | K468 | 10 g extractions |
Neprilysin Activity Assay Kit (Fluorometric) | K487 | 100 assays |
Diamine Oxidase Activity Assay Kit (Fluorometric) | K496 | 100 assays |
Histamine Assay Kit (Colorimetric) | K506 | 100 assays |
Multidrug Efflux Transporter (MDR1/P-gp) Ligand Screening Kit | K507 | 100 Assays |
Transglutaminase Inhibitor Screening Assay Kit | K508 | 100 assays |
Acidic Mammalian Chitinase Activity Kit (Fluorometric) | K513 | 100 assays |
3D Cell Culture Matrix Alginate Hydrogel Kit | K517 | 100 assays |
3D Cell Culture Matrix BME Kit | K518 | 100 assays |
3D Cell Culture Matrix Duo-Matrix Kit | K519 | 100 assays |
Factor XIIIa Activity Assay Kit (Colorimetric) | K522 | 100 assays |
Homocysteine Assay Kit (Fluorometric) | K531 | 100 assays |
α-L-Fucosidase Activity Assay Kit (Fluorometric) | K542 | 100 assays |
Acidic Mammalian Chitinase Inhibitor Screening Kit (Fluorometric) | K693 | 100 assays |
Human Hexokinase (HK) Inhibitor Screening Kit (Colorimetric) | K713 | 100 assays |
EZClick™ Protein Synthesis Monitoring Assay Kit (Microscopy) | K714 | 50 assays |
EZClick™ Protein Synthesis Monitoring Assay Kit (Flow Cytometry) | K715 | 50 assays |
Angiotensin II Converting Enzyme (ACE2) Activity Assay Kit (Fluorometric) | K897 | 100 assays |
Methanol Assay Kit (Colorimetric) | K898 | 100 assays |
Cell Transformation Assay Kit (Colorimetric) | K921 | 100 assays |
Total Phosphodiesterase Activity Assay Kit (Fluorometric) | K927 | 100 assays |
3D Cell Culture HTS Cell Viability Complete Assay Kit | K948 | 100 assays |
Prostate Specific Antigen (PSA) Activity Assay Kit (Fluorometric) | K962 | 100 assays |
Phospho-p38 MAPK (Thr180+Tyr182) Translocation Assay Kit (Cell-Based) | K965 | 100 assays |
Cholinesterase Activity Assay Kit (Colorimetric) | K975 | 100 assays |
Nitric Oxide Cell-Based HTS Assay Kit | K979 | 100 assays |
5-Lipoxygenase Inhibitor Screening Kit (Fluorometric) | K980 | 100 assays |
β-Xylosidase Activity Assay Kit (Fluorometric) | K981 | 100 assays |
Mutant Isocitrate Dehydrogenase (Mutant IDH) Activity Assay Kit (Colorimetric) | K985 | 100 assays |
Methyltransferase Activity Assay Kit (Colorimetric) | K986 | 100 assays |
Alkaline Sphingomyelinase Activity Assay Kit (Colorimetric) | K987 | 100 assays |
Plasma Kallikrein Inhibitor Screening Kit (Colorimetric) | K989 | 100 assays |
3D Cell Culture Ready-to-Use Scaffold Complete Kit | K990 | 100 assays |
Factor XIIa Activity Assay Kit (Colorimetric) | K994 | 100 assays |
Neprilysin Inhibitor Screening Kit (Fluorometric) | K996 | 100 assays |
Plasma Kallikrein Activity Assay Kit (Colorimetric) | K997 | 100 assays |
Monoclonal Anti-mouse pDC/IPC/CD317/BST2 (clone 120G8.04)
Dendritics generated rat monoclonal antibody (mAb) that recognizes mouse plasmacytoid dendritic cells (pDCs). The target molecule was found to be BST2 (bone marrow stromal cell antigen 2). This antibody, named 120G8, stains a small subset of CD11c-low spleen cells with high specificity. This population produces high amounts of IFNα upon in vitro viral stimulation. Both ex vivo- and in vitro-derived 120G8+ cells display a phenotype identical with that of mouse pDCs (B220-high Ly6C-high Gr1-low CD11b- CD11c-low). Mice treated with 120G8 mAb are depleted of B220-high Ly6C-high CD11c-low cells and have a much reduced ability to produce IFNα in response to in vivo CpG stimulation. mAb 120G8 stains all and only B220-high Ly6C-high CD11c-low pDC in all lymphoid organs. Immunohistochemical studies performed with this mAb indicate that pDC are
located in the T cell area of spleen, lymph nodes, and Peyer’s patches. Using 120G8 mAb in immunofluorescence studies demonstrates mouse strain- and organ-specific differences in the frequency of pDCs and other DC subsets (Asselin-Paturel C et al, 2003 ; J. Immunol., 172:6466; Blasius AI, 2006, J. Immunol., 177:3260 ; Goubier A et Al, 2008, Immunity, 29:464-475).
Clone: 120G8
Species: rat
Specificity: mouse pDCs/IFN producing cells (IPC) (extracellular domain)
Immunogen: mouse plasmatocytoid DCs (pDCs)
Isotype: IgG1/kappa
Species cross-reactivity: nd
Applications tested: Flow cytometry, in vivo depletion, IHC
Usage recommendation: This monoclonal antibody may be used between at 1-10 µg/ml. For pDCs in vivo depletion in Balb /c mice, mAb 120G8 was used between 50-200 µg /
injection.
http://www.dendritics.net/products/detail/ddx0390-120g8.04
防伪, 较真就要[一]码归一[码] R&D Systems, Tocris Bioscience, Novus Biologicals
科研中,大家对假货和以次充好深恶痛觉,因为假货不但造成可观的经济损失,导致的错误结果更可能让整个课题走上岔路。
对于知名品牌,假货就是潜伏在身后影子里的幽灵,品牌越高大,更长的影子也招来更多的幽灵。保障用户权利,驱散这些幽灵,Bio-Techne 和 ATCG 责无旁贷!
这次,我们给 R&D Systems ,Tocris Bioscience 和 Novus Biologicals 全线产品添加防伪码,让假货露出原形!
在新包装中,你可以找到 Bio-Techne 特色的重溶指南贴纸,防伪码就藏在这里的右下角:
刮开涂层,左侧的二维码一览无余,同时右侧的 16 位数字防伪码也完整呈现:
具体鉴别流程如下:
从「购买与防伪」菜单进入「防伪查询」
点击「扫一扫 查真伪」扫描刚刮开的二维码
根据返回的结果,您就可以确认是不是正品了:
发现假货,请立即通过技术支持电话向我们反馈,举报有奖
技术支持热线(工作日 8:30-17:30)
800-988-1270
400-821-347
好啦,了解了防伪码,认识了新包装,让科研更轻松,让生活更有乐趣!R&D Systems ,Tocris Bioscience 和 Novus Biologicals 的新包装产品,已经整装待发喽!
Recombinant Antibodies for Immunotherapy Research
At Absolute Antibody we have developed a collection of recombinant engineered antibodies against clinically relevant proteins, including homologues of current therapeutic targets. We can match the antibody species to the host organism and tailor the effector function, similar to how pharmaceutical companies develop human therapeutics.
Target (mouse) | Clone ID | Original Format |
CD134 | OX86 | Rat IgG1 |
CD200 | OX90 | Rat IgG2a |
CD28 | D665 | Mouse IgG1 |
CD28 | E18 | Mouse IgG2b |
CD47 | mIAP301 | Rat IgG2a |
GITR | YGITR 860.103.5 | Rat IgG2b |
GITR | YGITR 765 | Rat IgG2b |
GITRL | YGL 386 | Rat IgG1 |
ICOS | 7E.17G9 | Rat IgG2b |
LAG3 | YAML 555.6 | Rat IgG2b |
PD-1 | RMP1-14 | Rat IgG2a |
PD-L1 | alphaPD-L1 | Chicken scFv |
PD-L1 | YDC 127.1.1 | Rat IgG2a |
Antibodies against proteins involved in co-stimulation and other aspects of immune cell regulation are of particular interest to therapeutics developers. Some have already entered the clinic, with more in the development pipeline. However, many aspects of immune cell signalling are still unknown, and researchers require ever more advanced tools to tap into this potential.
At Absolute Antibody, we use recombinant technology to provide superior monoclonal antibody reagents at competitive prices. In particular we can modify antibody species and isotype for greater flexibility in vivo, for example we can readily generate mouse-anti-mouse or rat-anti-rat antibodies.
Why go recombinant?
Because of their recombinant manufacture our antibodies show minimal batch-to-batch variability and have potential for customisation. We can convert any antibody into any format allowing us to offer each specificity in a range of species, isotypes and subtypes. This means our customers may ‘build’ an antibody to best suit their experiment.
- Choose primary antibody format to suit your secondary reagent
- Choose antibody species to be compatible with your model organism
- Choose antibody isotype to investigate your chosen host responses (includes IgM and all IgG subtypes)
- Choose from a range of custom engineering options such as our Fc Silent format with reduced FcR binding to remove Fc receptor function, or other such formats found in the literature (e.g. IgG1-LALA, IgG1-D265A)
- Choose one of our listed antibodies, or apply our recombinant technology to your own clone. All our antibody services are royalty-free.
20% Off Sample Size Antibodies
20% Off Sample Size Antibodies for Novus antibodies.
View our sample size antibodies
Promo Code: SAMPLE2017.
Validity Period: May 5 – June 30, 2017.
Not valid in combination with other offers.
Soluble B7-H1/PD-L1 Levels in Multiple Cancer Subtypes: High Sensitivity Measurement by Immunoassay
Although the immune checkpoint protein B7-H1/PD-L1 is a commonly used cancer biomarker, controversy remains over the predictive and prognostic utility of immunohistochemical methods. Download our white paper which shows that we can reliably measure B7-H1/PD-L1 in conditioned media supernates and cell lysates from a number of cancer cell lines.
Data from our white paper indicate that:
- We can reliably measure B7-H1/PD-L1 in a number of human cancer cell lines
- Soluble B7-H1/PD-L1 expression levels are coincident with loss of PTEN tumor suppressor or increased activation of the phosphoinositide 3-kinase pathway
Request a copy:
The PD-1 / PD-L1 Pathway
Introduction
The immune system fights off pathogens, but this defensive force can be pathogenic itself when hyperactive, resulting in autoimmune diseases such as lupus and multiple sclerosis. Consequently, the body has developed multiple mechanisms to suppress the immune system when necessary.
One method of immunosuppression is the PD-1 pathway. This pathway is activated in response to the mobilization of the immune system. The receptor PD-1 is expressed on the surface of activated lymphocytes. Similarly, its ligand, PD-L1, is expressed by antigen-presenting cells in response to cytokine signaling. When PD-L1 is bound to PD-1, downstream signaling undoes the phosphorylation events associated with activation, thereby reverting lymphocytes to an inactive state [1, 2].
Antibody | Cat no. | Type | Applications |
PD-1/CD279 Antibody | 18106-1-AP | Rabbit Poly | ELISA, WB, FC, IHC |

Immunotherapy: A Promising Treatment for Cancer
Tumor cells take advantage of the PD-1 pathway to evade the immune system [3]. Consequently, many pharmaceutical companies have been developing drugs to inhibit PD-1 and PD-L1. In clinical trials, many patients have shown strong responses to these therapies [4-10]. For these drugs to be most effective, a high number of CD8+ T cells must already be at the tumor site, ready to be mobilized after inhibition of the PD-1 pathway [11].Recent investigations have uncovered promising methods of increasing the efficacy of PD1 inhibitors. One method is combining PD1 inhibitors with other drugs, such as HDAC inhibitors [12] and anti-CTLA4 antibodies [9]. Another method is using biomarkers to predict response to therapy [13,14]. Recent work has also suggested that GSK3 inhibitors can enhance effects of immunotherapy [15].Though these results have been encouraging, several challenges remain, including the mitigation of autoimmune effects and how to overcome drug resistance.
Current Antibody Drug Development
Drug | Company | |
PD-1 | SHR-1210 | Incyte |
Nivolumab | Bristol-Myers Squibb | |
Pembrolizumab | Merck | |
Pidilizumab | CureTech | |
BMS 936559 | Bristol-Myers Squibb | |
PD-L1 | Atezolizumab | Roche |
Durvalumab | AstraZeneca | |
Avelumab | Pfizer/Merck | |
MDX-1105 | Bristol-Myers Squibb | |
CTLA-4 | Ipilimumab | Bristol-Myers Squibb |
Tremelimumab | Pfizer/AstraZeneca |
Antibody | Cat no. | Type | Applications |
PD-L1/CD274 Antibody | 17952-1-AP | Rabbit Poly | ELISA, IF, IHC, IP, WB |
KD/KO Validated, 9 Publications

Related Products
Antibody | Cat no. | Type | Applications |
PD-L1/CD274 | 66248-1-Ig | Mouse mono | ELISA, WB, IHC, IF, FC |
CD86/CTLA 4 | 13395-1-AP | Rabbit poly | ELISA, WB, FC |
CD3 epsilon | 17617-1-AP | Rabbit poly | ELISA, WB, IHC, IP, FC |
GSK3B | 22104-1-AP | Rabbit poly | ELISA, WB, IHC, IF, IP |
BRAF | 20899-1-AP | Rabbit poly | ELISA, IHC, IF |
References
1. Ohegbulam et al. (2015) Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 21:24-33.
2. Haanen, J. (2013) Immunotherapy of Melanoma. EJC Suppl 11:97-105.
3. Yao et al. (2013) Advances in targeting cell surface signaling molecules for immune modulation. Nat Rev Drug Discov. 12:130-146.
4. Topalian, S. et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366:2443-2454.
5. Hamid, O. et al. (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369:134-144.
6. Topalian, S. L. et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366:2443–2454
7. Brahmer, J. R. et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366:2455–2465
8. Hamid, O. et al. (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369:134–144
9. Wolchok, J. D. et al. (2013) Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369:122–133
10. Topalian, S. L. et al. (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32:1020–1030
11. Tumeh, P. et al. (2014) PD-1 blockade induces responses by inhibiting adaptive immune response. Nature. 515:568-71.
12. Woods, D. et al. (2015) HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade. Cancer Immunol Res 12:1375-85.
13. Chakravarti, N., & Prieto, V. G. (2015). Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis. Translational Lung Cancer Research, 4:743–751.
14. Barak, V. et al. (2015) Assessing response to new treatments and prognosis in melanoma patients, by the biomarker S-100B. Anticancer Res. 35:6755-60.
15. Taylor, A. et al. (2014) Glycogen synthase kinase 3 inactivation drives T-bet-mediated downregulation of co-receptor PD-1 to enhance CD8+ cytolytic T cell responses. Immunity 44:274-86.
Liver Diseases
Mac-2 binding protein (Mac-2bp), known as 90K, is a highly N-glycosylated, secreted protein, identified as a ligand of Galectin-3. It is considered that through interaction with Galectin-3, Mac-2bp promotes homotypic cell-cell contact or regulates cell adhesion. And it has been reported that Mac-2bp levels in blood have associations with various cancers and chronic hepatic diseases such as NASH (Non-Alcoholic Steatohepatitis).
27362 Human Mac-2 binding protein (Mac-2bp) Assay Kit – IBL
27796 Mouse Mac-2 binding protein (Mac-2bp) Assay Kit – IBL
Hepatocyte growth factor/scatter factor (HGF) is a liver regeneration and growth factor that was isolated and purified from the plasma of the person who suffers fulminant hepatitis. In addition blood and tissue concentrations being assessed during liver injury, increases in concentration in body fluids have been reported in other types of disease besides liver disease (e.g., inflammatory diseases, neoplastic diseases, and fibrosis). HGF is secreted as an inactive single-chain pro-form, and it exerts its physiological activity after processing by HGF activator (HGFA), coagulation factor VIIa, etc., and conversion to activated HGF, a heterodimer. This product is a kit that measures human HGF by the WHO standard.
27402 Human Total HGF Assay Kit
c-Met, the product of c-met gene has been reported to be the HGF receptor since HGF induces phosphorylation of c-Met by binding specifically to it. It is a heterodimer protein composed of an α-chain that is linked to a β-chain. The β-chain has the intracellular tyrosine kinase domain, the transmembrane domain and the extracellular domain, and it is tied into the α-chain that is the extracellular domain of c-Met. c-Met exists mainly in epidermal cells. It is found in the digestive tract, prostate gland, seminal vesicles, mammary gland, microglia cells, monocytes and macrophages, and more amount in the liver and kidney. It is considered that c-Met tansmits signals resulting from binding to HGF, such as growth, motility and organ formation, in the organs and cells mentioned above. This kit is designed to measure Human c-Met.
Kidney Diseases
IBL – New Company Info
https://www.ibl-japan.co.jp/files/user/pdf/en/company-profile.pdf
IBL- Kidney Disease
https://www.ibl-japan.co.jp/en/kidney_disease/
α-Klotho (Alpha Klotho) was identified as an extremely down-regulated gene in the genetically-modified mouse of which phenotype is very similar to various symptoms of human aging. The sequences of Alpha Klotho genes have been identified in various species including humans based on the one of mouse. Alpha Klotho protein is a 130 kDa, one-transmembrane protein and its expression is confirmed in the kidneys and the parathyroid glands. In recent years, it has become clear that Alpha Klotho is an important molecule within a living organism regulating the metabolism of mineral such as calcium and phosphorus. It is considered that in Alpha Klotho mouse, early aging-like symptoms are induced by impaired mineral homeostasis caused by decreased expression of Alpha Klotho. Meanwhile, it is reported that the long N-terminal extracellular domain which comprises the major portion of sequence of Alpha Klotho protein is released free into blood by shedding. However, there are many unclear points about functions and changes in concentration of free (soluble) Alpha Klotho protein, so it was required to develop the measurement system of Alpha Klotho.
27998 Human soluble α-Klotho Assay Kit – IBL
27601 Mouse soluble α-Klotho Assay Kit – IBL
Galactose-deficient IgA1 (Gd-IgA1) attracts a lot of attentions as a critical effector molecule in the pathogenesis and progression of IgA nephropathy (IgAN) in recent studies. It has been suggested that several O-link glycans modified regions exist in the heavy chain hinge region of human IgA1 molecule andGd-IgA1 circulates in blood stream of the patients with the pathological condition of IgAN. The measuring system using snail (helix aspersa; HAA) lectin that is extracted from snail has been used in past numerous studies and it was revealed that serum levels of Gd-IgA1 in patients with IgAN is significantly elevated compared with the level of healthy subjects or patients with renal diseases other than IgAN. Thus, the importance and purpose of measuring serum Gd-IgA1 level have been gradually recognized from such studies.
However, since the measuring system used HAA lectin is not suitable for measuring multiple and massive samples in large scale studies due to its instability of glycan-recognizing activity, development of alternative measuring system that can quantitatively measure human Gd-IgA1 in serum with stable and reliable data has been considered as an essential and urgent matter. This IBL ELISA kit using the monoclonal antibody that specifically recognizes galactose-deficient hinge sequence of human Gd-IgA1 is a lectin non-dependent measuring system that can quantitatively measure Gd-IgA1 in human serum,which is also suitable for large scale studies because of its stability.
27600 Gd-IgA1 (Galactose-deficient IgA1) Assay Kit – IBL
Osteopontin (OPN) is a secretory glycoprotein first isolated from the bone. At present, it is known as a highly acidic calcium-binding phosphorylated protein with sugar chain bonds, that is secreted from diverse cells, including osteoblasts, renal tubular cells, macrophages, activated T lymphocytes and vascular smooth muscle cells. Its molecular weight can vary depending on the sugar chain formation and phosphorylation, and has been reported to range from 44 to 66 kDa. One major characteristic of OPN is that its molecule contains an Arg-Gly-Asp (RGD) amino acid sequence. This motif is also seen in fibronectin, vitronectin and other extracellular proteins. It is known that OPN binds through this motif to members of the integrin family (e.g., αvβ3) of cell surface receptors. Another unique characteristic of OPN is that it can assume various molecular forms in vivo by undergoing RNA splicing, saccharification, phosphorylation, sulfation, degradation by protease, etc. OPN is considered to coexist with thrombin locally in tissues such as injured tissue, inflamed tissue, vascularized tissue, and tumor tissue. Coexistence with thrombin increases the likelihood of proteolysis, and this process may have an important physiological role. The cleavage of OPN with thrombin causes the hidden sequence of the adhering sites to be exposed. It has been reported that the fragments of OPN produced following cleavage by thrombin react with α9β1 integrin. Furthermore, in view of the finding that OPN has many cell-binding sites and can react with various receptors, interactions between OPN and these cells or receptors may play some unknown roles. This kit can specifically measure the N-terminal OPN fragment (hereinafter called “OPN N-Half”) cleaved by thrombin. OPN molecules without thrombin cleavage, on the other hand, are hardly detected by the kit.
27258 Human Osteopontin N-Half Assay Kit – IBL
27259 Mouse Osteopontin N-Half Assay Kit – IBL
c-Met, the product of c-met gene has been reported to be the HGF receptor since HGF induces phosphorylation of c-Met by binding specifically to it. It is a heterodimer protein composed of an α-chain that is linked to a β-chain. The β-chain has the intracellular tyrosine kinase domain, the transmembrane domain and the extracellular domain, and it is tied into the α-chain that is the extracellular domain of c-Met. c-Met exists mainly in epidermal cells. It is found in the digestive tract, prostate gland, seminal vesicles, mammary gland, microglia cells, monocytes and macrophages, and more amount in the liver and kidney. It is considered that c-Met tansmits signals resulting from binding to HGF, such as growth, motility and organ formation, in the organs and cells mentioned above. This kit is designed to measure Human c-Met.